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Introduction
Type 2 diabetes is a progressive continuing metabolic
disorder characterised by hyperglycaemia caused by
insulin deﬁciency usually on a background of insulin
insensitivity (1). As the condition progresses endoge-
nous insulin production declines and most people
require insulin therapy (2). Starting insulin results in
a clinically relevant improvement in glycated haemo-
globin (HbA1c) level of around 1.5–3.5% (3,4), and
while a number of insulin regimens can be used,
clinical decisions about the optimal choice of initial
therapy often seem arbitrary (5).
Insulins differ in molecular structure, pharmaco-
kinetic and pharmacodynamic properties, and in
clinical outcomes. neutral protamine Hagedorn
(NPH) insulin has peak absorption around 4–6 h
after injection with a fairly rapid decline thereafter
(6), while premixed biphasic insulin (premix) com-
bines basal and short or rapid acting meal-time
insulins, the intermediate-acting component being
similar to NPH (7). Insulin detemir (detemir) and
insulin glargine (glargine) are long-acting human
insulin analogues (8,9) providing relatively peak-free
insulin levels and longer coverage compared with
NPH.
SUMMARY
Aims: Insulin is normally added to oral glucose-lowering drugs in people with type
2 diabetes when glycaemic control becomes suboptimal. We evaluated outcomes
in people starting insulin therapy with neutral protamine Hagedorn (NPH), detemir,
glargine or premixed insulins. Methods: Insulin-naı¨ve people with type 2 diabetes
(n = 8009), ‡ 35 years old, HbA1c ‡ 6.5% and begun on NPH (n = 1463), det-
emir (n = 357), glargine (n = 2197) or premix (n = 3992), were identiﬁed from a
UK database of primary care records (The Health Improvement Network). Unad-
justed and multivariate-adjusted analyses were conducted, with persistence of insu-
lin therapy assessed by survival analysis. Results: In the study population
(n = 4337), baseline HbA1c was 9.5 ± 1.6%, falling to 8.4 ± 1.5% over
12 months (change )1.1 ± 1.8%, p < 0.001). Compared with NPH, people taking
detemir, glargine and premix had an adjusted reduction in HbA1c from baseline, of
0.00% (p = 0.99), 0.19% (p < 0.001) and 0.03% (p = 0.51). Body weight
increased by 2.8 kg overall (p < 0.001), and by 2.3, 1.7, 1.9, and 3.3 kg on NPH,
detemir, glargine and premix (p < 0.001 for all groups); insulin dose at 12 months
was 0.70 (overall), 0.64, 0.61, 0.56 and 0.76 U⁄kg⁄day. After 36 months, 57%
of people on NPH, 67% on glargine and 83% on premix remained on their initially
prescribed insulin. Discussion and Conclusion: In routine clinical practice, peo-
ple with type 2 diabetes commenced on NPH experienced a modest disadvantage
in glycaemic control after 12 months compared with other insulins. When compar-
ing the insulins, glargine achieved best HbA1c reduction, while premix showed
greatest weight gain and the highest dose requirement, but had the best persis-
tence of therapy.
What’s known
• Type 2 diabetes is a progressive continuing
metabolic disorder in which most people require
insulin therapy as endogenous insulin production
declines and glycaemic control becomes
suboptimal.
• Various insulin preparations are available, each
showing differences in molecular structure,
pharmacokinetic and pharmacodynamic properties
and in clinical outcomes.
• Few studies have made multiple comparisons of
different insulin preparations used to begin
insulin therapy in people with type 2 diabetes.
What’s new
• In this observational study of people with type 2
diabetes with suboptimal glycaemic control using
oral glucose-lowering drugs and ⁄ or lifestyle
therapy, signiﬁcant improvements in glycaemic
control were demonstrated after commencing one
of four insulin preparations – NPH, detemir,
glargine or premix.
• People commenced on NPH insulin had a modest
overall disadvantage in outcomes when compared
with other insulins.
• Between group comparisons showed that
improvements in glycaemic control were greater
with insulin glargine, while persistence with
therapy was best on premix at a cost of modestly
greater weight gain and higher insulin dosage.
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doi: 10.1111/j.1742-1241.2010.02520.x 1609A number of comparative studies have evaluated
the various insulin preparations used to begin insulin
therapy in people with type 2 diabetes (10–14). The
ﬁndings in terms of reductions in HbA1c, change in
body weight and incidence of hypoglycaemia events
have varied, while only a few studies have made mul-
tiple comparisons of the different treatment options
(15,16).
To help resolve some of these issues, and to obtain
data from real clinical practice, we have conducted
an observational study of changes in glycaemic con-
trol, body weight, oral glucose-lowering drug
(OGLD) use and insulin dose in people with type 2
diabetes who began one of four insulin types – NPH,
detemir, glargine or premix. Our retrospective analy-
sis of a nationwide primary health care database is
intended to supplement evidence from prospective
non-randomised studies such as PREDICTIVE
(17,18). For all insulins except detemir, data were
available to 3 years and were used to assess changes
over the longer term.
Database and methods
Data source
Anonymised data were sourced from a large national
(UK) computerised medical record database known
as The Health Improvement Network (THIN), which
contains longitudinal data collected from UK pri-
mary care practices (19). At the time of study, the
THIN database included data from 211 practices
over a 15-year period, with 2,335,667 people fol-
lowed prospectively. The THIN database is not sup-
ported by any industrial sponsor. Data are collected
in routine care during daily record keeping within
practices, and are anonymised using encrypted iden-
tiﬁers for the physician and individual.
From data collected between July 2002 and
December 2006, as previously described (20,21),
174,094 people were identiﬁed with a relevant medi-
cal diagnosis (22), or through prescriptions of OGLD
therapy. Data were also extracted on diabetic comor-
bidities. Ethical approval for this study was obtained
from the London Multiple Research Ethics Commit-
tee (Number 06⁄MRE02⁄32) before commencing
data extraction.
Individuals included in this analysis were required
to have not been prescribed insulin within
12 months, been started on NPH, detemir, glargine
or premix, with or without meal-time insulin and
not have switched to another insulin within
12 months (Figure 1). To reduce the possibility that
people with type 1 diabetes would be included in the
analysis anyone < 35 years old was excluded, and to
reduce insulin starting errors a baseline HbA1c level
of ‡ 6.5% was imposed. Use of analogue and human
premix insulins could not be distinguished from
information collected.
Design and outcome measures
This was a retrospective, 36-month, non-randomised
observational study of prospectively collected data.
The principal outcome was pre-deﬁned as change in
HbA1c at 12 months. Measurements were performed
locally. Although much of the UK is currently HbA1c
DCCT-aligned, and primary care practices use
National Health Service hospital laboratories which
are members of quality assurance schemes, the degree
of assay standardisation at the time of data collection
(2002–2006) is not known. This study, however,
depends on change in HbA1c and will thus be less
sensitive to differences in calibration between assays.
HbA1c data were analysed for 3-month intervals
prior to, and following, beginning insulin therapy
using either actual or linearly interpolated values.
Secondary outcomes included change in HbA1c at
36 months, change in body weight, number of pre-
scribed OGLDs over 12 months, daily insulin dose, the
use of meal-time insulin and the proportion of people
achieving UK speciﬁc treatment targets of HbA1c
£ 7.5% and reductions ‡ 1.0% (23). Persistence of use
of ﬁrst prescribed insulin was calculated. Self-reported
episodes of hypoglycaemia were recorded by general
practitioners (GPs) duringeach3 monthly interval.
Statistical methods
Unadjusted and multivariate-adjusted analyses were
conducted. For the unadjusted analyses of change in
174,094 people with diagnosis of 
"diabetes" or prescribed an OGLD
2002-December 2006
13,387 people identified with
type 2 diabetes with 12 months of 
data and not on insulin at baseline
8009 people starting insulin therapy
4337 people with HbA1c
measurement in the quarter prior 
to insulin and at 12 months
160,707 people on insulin
treatment at baseline
5378 people aged < 35 years
or with baseline HbA1c < 6.5%
Figure 1 Disposition of participants entering the study
from the THIN database. HbA1c, glycated haemoglobin;
OGLDs, oral glucose-lowering drugs; THIN, The Health
Improvement Network
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were required to have an assessment at baseline and
data at 12 months or data allowing linear interpola-
tion of such an estimate. Multivariate analysis was
used to adjust for baseline characteristics and con-
founding variables in the analysis of HbA1c-related
outcomes.
For the unadjusted analyses, linear interpolation of
missing data was performed where a patient had at
least two data measurements during each 12-month
period (prior to and following commencement of
insulin) and data were not missing for two consecu-
tive 3-month intervals. For clarity, linearly interpo-
lated data were used to display changes in different
outcomes over different time periods.
For change in HbA1c a multivariate analysis, using
patient data, was performed using multiple linear
mixed regression analyses, adjusted for repeated mea-
sures, with change in HbA1c from baseline as the
dependent variable and the following pre-deﬁned
(ﬁxed-effects) exploratory covariates: baseline HbA1c,
hypoglycaemia, number of OGLDs, insulin type,
mean increase in HbA1c in the 12 months prior to
insulinisation, comorbidities prior to commencing
the study (pre 2002), concurrent meal-time insulin
usage, weight, age, gender, disease duration and asso-
ciated comorbidities during the study. Differences in
the standard of care among general practices were
modelled treating practice as a random-effect in the
mixed-effects framework; a two-level model was cre-
ated with patient (level 1) and practice (level 2) as a
grouping variable. Treating practice as a random
effect explicitly acknowledges that the THIN data are
drawn from a larger pool of all practices in the UK.
For the results of change from baseline to 12 months
overall differences between insulins were analysed,
then, where p < 0.05, pairwise comparisons of
groups were performed using unpaired t-tests.
To adjust for differences in insulin dose between
treatments, a standardised measure of glycaemic con-
trol was constructed and assessed by multivariate
analysis. The ratio of each patient’s mean daily basal
insulin dose over 12 months (and 36 months) to the
mean basal dose of all people on all treatments was
calculated. This ratio was then used to adjust for
changes in HbA1c, forming the dependent variable in
a multivariate model and adjusting for the same set
of ﬁxed and random covariates. For the ‘standar-
dised’ basal dose analysis, premix was not included
as it contains meal-time insulin.
Sensitivity analyses were performed to investigate
the effect of baseline HbA1c levels above 8.0% and
10.0% on the primary outcome. Secondary outcomes
(body weight, insulin dose, hypoglycaemia and
OGLDs) and the percentage of patients achieving
target HbA1c levels were summarised descriptively.
Additionally, the proportion of people reaching an
HbA1c level of 7.5% and the proportion of people
achieving ‡ 1.0% reduction in HbA1c were compared
pairwise in logistic mixed-effects models within the
generalised linear mixed modelling framework and
presented as odds ratios. Persistence on the ﬁrst
prescribed insulin was calculated as a function of
duration on that insulin by survival analysis with
censoring at the end of the study period.
Multivariate models were developed with SPSS for
Windows (version 8; SPSS, Chicago, IL, USA) using
a backward stepwise approach. Variables found to be
non signiﬁcant, but that were a priori expected to be
important in explaining variation in the dependent
variable and contributed to a better overall model
speciﬁcation, were kept in the model (24).
Results
Study population
A total of 8009 people with type 2 diabetes met the
inclusion criteria (Figure 1). Of these, 4337 (54.2%)
had an HbA1c measurement at baseline and
12 months. Baseline characteristics for the two popu-
lations did not differ materially (Table 1). Premixes
were the most commonly prescribed insulins (49.8%
of all people), detemir the least (4.5%). The latter
insulin was only available for use in the UK since
mid 2004. No clinically meaningful differences were
found between the therapy groups. Overall glucose
control was very poor before commencing insulin
(HbA1c 9.5 ± 1.6%). The use of OGLDs was similar
across the groups prior to insulin therapy.
Glycated haemoglobin
Overall, HbA1c increased by 0.56% (from 8.93% to
9.49%) in the 12 months prior to beginning insulin,
and fell by 1.1% (from 9.5% to 8.4%, p < 0.001)
over the 12 months thereafter (Figure 2A, Table 2).
The fall in HbA1c stabilised by 9 months, but with
further small reductions over the following 2 years
(Figure 2B). By 12 months, unadjusted decrease in
HbA1c from baseline was signiﬁcant in all insulin
groups (all p < 0.001). The HbA1c decrease was
greatest for glargine and premix (both )1.2%), and
least for NPH ()0.9%).
After adjustment for signiﬁcant and clinical covari-
ates, there was a signiﬁcant difference in HbA1c
between the groups (p < 0.001) (Table 3). Pairwise
comparisons for reductions in HbA1c at 12 months
with each insulin vs. NPH were only signiﬁcant for
glargine treatment ()0.19%, p < 0.001). Signiﬁcantly
greater decreases were also observed for the compari-
sons of glargine vs. detemir and glargine vs. premix;
Comparison of insulins in type 2 diabetes 1611
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Figure 2 Mean change in HbA1c over 12 and 36 months. The last measurement prior to commencing insulin is at
)3 months from initiation. Based on interpolated data. (A) Unadjusted change in HbA1c over 12 months before and after
commencing insulin. (B) Unadjusted change in HbA1c over 36 months after commencing insulin based on interpolated
data. Data not available for detemir. (C) Dose-adjusted change in HbA1c in the 12 months after commencing insulin.
Premix not included as it is a basal–bolus mixture. (D) Dose-adjusted change in HbA1c over 36 months. Premix not
included as only basal–bolus mixture. Data not available for detemir. HbA1c, glycated haemoglobin; NPH, neutral
protamine Hagedorn
Table 1 Baseline characteristics of new users of insulin in the quarter prior to commencing insulin therapy for all
starters and for those with an HbA1c measurement at baseline and 12 months
Parameter Detemir Glargine NPH Premix Total
All insulin starters
People, n (%) 357 (4.5) 2197 (27.4) 1463 (18.3) 3992 (49.8) 8009 (100)
Age (years) 58.9 ± 12.1 61.1 ± 12.2 60.7 ± 12.3 61.3 ± 11.6 61.0 ± 11.9
Gender (% male) 47.0 45.0 46.0 43.0 44.0
Body weight (kg) 87.8 ± 22.6 87.4 ± 18.8 88.1 ± 20.1 83.8 ± 18.6 85.4 ± 19.2
Duration of diabetes (years) 5.7 ± 4.9 6.2 ± 5.2 6.1 ± 5.5 6.0 ± 5.6 6.0 ± 5.5
HbA1c (%)§ 9.6 ± 1.7 9.5 ± 1.5 9.4 ± 1.6 9.5 ± 1.7 9.5 ± 1.6
OGLDs prescribed, n* 2.02 ± 0.65 2.01 ± 0.62 1.95 ± 0.63 1.92 ± 0.63 1.96 ± 0.63
With HbA1c result at baseline and 12 months
People, n (%) 114 (2.6) 968 (22.3) 727 (16.8) 2528 (58.3) 4337
Age (years) 58.4 ± 11.8 60.1 ± 11.7 59.8 ± 12.4 61.5 ± 11.2 60.8 ± 11.6
Gender (% male) 49.1 45.9 47.3 44.9 45.6
Body weight (kg) 84.9 ± 21.5 87.2 ± 18.9 87.8 ± 21.1 83.7 ± 18.6 85.3 ± 19.3
Duration of diabetes (years) 5.6 ± 4.7 6.4 ± 5.5 5.6 ± 4.7 6.2 ± 5.8 6.2 ± 5.6
HbA1c (%) 9.6 ± 1.7 9.5 ± 1.5 9.4 ± 1.6 9.5 ± 1.7 9.5 ± 1.6
OGLDs prescribed, n 2.01 ± 0.65 2.03 ± 0.61 2.01 ± 0.65 1.93 ± 0.61 1.96 ± 0.62
Data expressed as mean ± SD unless indicated. Data on ethnic origin were not available. HbA1c, glycated haemoglobin; NPH, neutral
protamine Hagedorn; OGLDs, oral glucose-lowering drugs. *Data for OGLDs based on data for 331 people on detemir, 2034 on glar-
gine, 1215 on NPH and 3317 on premix. Percentages relate to the proportion of patients in each group of the 4337 patients who
had a HbA1c result at baseline and at 12 months. Data for OGLDs based on data for 109 people starting detemir, 907 on glargine,
556 for NPH and 2528 for premix. §Data based on the 4337 patients who had a HbA1c result at baseline and at 12 months.
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data were available for detemir. After dose adjust-
ment (not premix) the ﬁndings were similar at both
12 and 36 months with somewhat larger differences
(0.3%) for the comparisons of glargine vs. NPH or
detemir (Figures 2C,D).
Sensitivity analyses showed that higher baseline
HbA1c levels were correlated with greater reductions
over the study periods; for example, the dose
adjusted HbA1c change for glargine vs. NPH
increased from )0.30 (overall) to )0.47% in people
with baseline HbA1c > 10.0% and from )0.29 to
)0.37% for the comparison glargine vs. detemir
(Table 3).
The proportion of people reaching an HbA1c tar-
get of £ 7.5% was similar between the insulins
(Table 2). Using logistic regression, the odds of
reaching that target at 12 months compared with
NPH were similar for premix and glargine [odds
ratio (OR) 1.63 and 1.65, p = 0.01] (Table 3). Other
comparisons were not statistically signiﬁcant. The
odds of achieving reductions in HbA1c ‡ 1.0% were
similar with glargine and premix, both of which were
signiﬁcantly greater compared with NPH and
detemir.
OGLD usage and insulin dose
The number of concomitant OGLDs used fell
(p < 0.001) with insulin treatment, from overall
mean of 1.96 in all people (individual insulin range
1.92–2.02) per day at baseline (Table 1) to mean of
1.17 (1.04–1.31) at 12 months; a change of between
)0.76 types⁄day with glargine and )1.03 types⁄day
with premix (Table 2, Figure 3A).
Following initiation, basal insulin doses increased
gradually over the year, but mostly in the ﬁrst
3 months (Figure 3B). Total daily insulin doses,
including meal-time insulin, were lower with glargine
(0.66 ± 0.49 U⁄kg) and highest with NPH insulin
(0.81 ± 0.88 U⁄kg) (Table 2). The proportion of
Table 2 Unadjusted outcomes for people with type 2 diabetes starting different insulins
Parameter Detemir Glargine NPH Premix Total
Insulin dose at 12 months (U⁄kg⁄day)
n (basal⁄total) 101⁄101 896⁄906 625⁄673 2317⁄2380 3939⁄4060
Basal 0.61 ± 0.48 0.56 ± 0.40 0.64 ± 0.72 0.76 ± 0.54 0.70 ± 0.56
Total* 0.72 ± 0.49 0.66 ± 0.49 0.81 ± 0.88 0.78 ± 0.55 0.76 ± 0.60
HbA1c (%)
n 114 968 727 2528 4337
12 months 8.5 ± 1.6 8.3 ± 1.3 8.4 ± 1.5 8.3 ± 1.5 8.4 ± 1.5
Change from baseline )1.0 ± 2.0 )1.2 ± 1.7 )0.9 ± 1.6 )1.2 ± 1.8 )1.1 ± 1.8
Achieving target (%)
£ 7.5% 28 30 27 33 31
‡ 1.0% reduction 39 57 47 58 55
Body weight (kg)
n 101 897 665 2329 3992
12 months 89.5 ± 21.6 89.4 ± 19.1 90.4 ± 21.3 87.1 ± 18.9 88.3 ± 19.5
Change from baseline +1.7 ± 5.2 +1.9 ± 6.9 +2.3 ± 5.2 +3.3 ± 5.7 +2.8 ± 6.0
OGLDs prescribed, n
n 96 792 378 1072 2339
12 months 1.27 ± 0.51 1.31 ± 0.47 1.25 ± 0.45 1.04 ± 0.21 1.17 ± 0.39
Change from baseline )0.83 ± 0.72 )0.76 ± 0.66 )0.82 ± 0.68 )1.03 ± 0.60 )0.90 ± 0.65
Persistence with therapy, n (%)
Baseline 357 2197 1463 3992 –
12 months 209 (78) 1538 (83) 1042 (75) 3227 (92) –
24 months 61 (68) 897 (75) 743 (65) 2367 (87) –
36 months § 385 (67) 468 (57) 1602 (83) –
Use of a meal-time insulin (%)
0–12 months 20 14 22 6 12
Data expressed as mean ± standard deviation (SD) or n (%) unless indicated. HbA1c, glycated haemoglobin; NPH, neutral protamine
Hagedorn; OGLDs, oral glucose-lowering drugs. *Total daily insulin doses include basal plus meal-time insulin; p < 0.001, Number
(%) of people on initial insulin therapy after censoring. §Persistence data for detemir were not available at 36 months as the drug was
only licensed in the UK from mid 2004.
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12 months NPH, detemir or glargine was 22% for
NPH, 20% for detemir and 14% for glargine.
Body weight and hypoglycaemia
People generally gained weight on all regimens
(p < 0.001 overall), with a weight (kg) increase at
12 months; ranging from 1.7 ± 5.2 (SD) kg on det-
emir, 1.9 ± 6.9 kg on glargine, 2.3 ± 5.2 kg on NPH
and 3.3 ± 5.7 kg on premix (Table 2, Figure 3C).
People who were on oral agents during the
12 months prior to commencing insulin reported
645 hypoglycaemic episodes (0.11 events per patient-
year); 0.08 episodes per patient⁄year for NPH, 0.10
for premix, 0.13 for glargine, and 0.14 for detemir.
Reported events per patient-year remained low dur-
ing the 12 months after starting insulin: 0.12 for det-
emir, 0.14 for NPH, 0.18 for glargine and 0.25 events
per patient-year for premix.
Persistence
After 12 months, 75% of people on NPH remained
on the insulin, compared with 78% for detemir, 83%
for glargine and 92% for premix (Table 2, Figure 4).
At 36 months, this order was unchanged (no data
for detemir), with signiﬁcant between group differ-
ences (p < 0.001). Pairwise comparison at 36 months
showed premix persistence was better than for other
insulins (all p < 0.001). At 24 months, glargine per-
sistence was better than detemir (p = 0.014) and at
36 months it was better than NPH (p < 0.001).
Discussion
This non-interventional study assessed clinical out-
comes in people with type 2 diabetes starting insulin
therapy using each of the four usual insulin prepara-
tions. Baseline HbA1c was well above recommended
thresholds for starting insulin (4,5), as has been well
recognised in other studies (15,17). Part of the rea-
son for this was a rapid deterioration in blood glu-
cose control in the year before starting therapy. At
12 months, insulin therapy was an effective strategy
in reducing HbA1c in a population with a very
diverse duration of diabetes (SD 5–6 years), but the
reduction of a little over 1.0% is somewhat disap-
pointing compared with treat-to-target studies
(14,25), despite similar insulin doses at 1 year. How-
Table 3 Comparative adjusted reduction in HbA1c in people with type 2 diabetes commencing insulin
Parameter
HbA1c reduction (% units)
Detemir vs.
NPH
Glargine vs.
NPH
Premix vs.
NPH
Glargine vs.
Detemir
Glargine vs.
Premix
Premix vs.
Detemir
Change in HbA1c at 12 months
Overall )0.00 ± 0.08 )0.19 ± 0.04 )0.03 ± 0.04 )0.19 ± 0.07* )0.16 ± 0.03 )0.03 ± 0.07
Baseline ‡ 8.0% )0.02 ± 0.09 )0.25 ± 0.05 )0.05 ± 0.04 )0.23 ± 0.08* )0.20 ± 0.04 )0.03 ± 0.08
Baseline ‡ 10.0% )0.09 ± 0.15 )0.27 ± 0.09* )0.01 ± 0.08 )0.36 ± 0.14* )0.26 ± 0.07 )0.09 ± 0.14
Dose-adjusted change in HbA1c at 12 months
Overall )0.01 ± 0.13 )0.30 ± 0.06 )0.29 ± 0.12* 
Baseline ‡ 8.0% )0.08 ± 0.15 )0.41 ± 0.07 )0.33 ± 0.14* 
Baseline ‡ 10.0% )0.10 ± 0.25 )0.47 ± 0.14 )0.37 ± 0.25 
Change in HbA1c at 36 months
Overall – )0.12 ± 0.04* )0.03 ± 0.04 – )0.09 ± 0.03* –
Baseline ‡ 8.0% – )0.18 ± 0.05 )0.06 ± 0.05 – )0.12 ± 0.04* –
Dose-adjusted change in HbA1c at 36 months
Overall – )0.31 ± 0.08 –  –
Baseline ‡ 8.0% – )0.40 ± 0.09 –  –
Baseline ‡ 10.0% – )0.56 ± 0.17 –  –
Odds ratio for HbA1c reduction [OR (95% CI), p-value]
to £ 7.5% 1.52 (0.63–2.42),
0.35
1.65 (1.11–2.46),
0.01
1.63 (1.25–2.01),
0.01
1.24 (0.53–2.92),
0.62
0.96 (0.71–1.28),
0.77
1.42 (0.61–3.26),
0.41
‡ 1.0% 0.20 (0.07–0.57),
0.03
1.63 (1.08–2.46),
0.02
1.73 (1.33–2.74),
0.006
3.45 (2.79–4.24),
0.001
0.99 (0.74–1.34),
0.99
4.77 (1.83–12.4),
0.002
Data expressed as mean ± standard deviation (SD) unless indicated. p < 0.001 for all between-group differences for all outcomes
except unadjusted change at 36 months (p = 0.009). Comparisons with insulin detemir were not possible at 36 months as this insulin
was only available in the UK from mid 2004. HbA1c, glycated haemoglobin; NPH, neutral protamine Hagedorn. *p < 0.05. 
p < 0.001. Analysis not performed as dose adjustment for premix insulin was not possible because of meal-time component.
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mic control was maintained over the 3 years of
study. The reduction in use of concomitant OGLDs
indicates that additional use of these treatments may
have been associated with further improvement in
glycaemic control.
Those begun on NPH insulin had rather lesser
improvements in HbA1c than for the other insulins.
However, after adjustment for other variables, NPH
and premix did not differ at 12 or 36 months, but
the overall change with insulin glargine was about
0.2% units better at 12 months compared with NPH,
premix and detemir. This effect was larger in people
with higher baseline HbA1c levels. Comparisons with
detemir are less certain because of small number of
patients on this treatment, but the analysis suggested
that this too did not differ from NPH insulin. Incor-
porating dose adjustment in the analysis showed
improved glycaemic control with glargine compared
with both NPH and detemir.
In general, improvements in blood glucose con-
trol can only be judged in the context of hypo-
glycaemia incidence as well as insulin dose. Here
our data are unhelpful. The hypoglycaemia data in
the THIN database rely on people self-reporting
events to their GPs, and it is clear that even allow-
ing for the relative hyperglycaemia, the event rates
reported here are likely to be severe underestimates
of what is normally observed. Another plausible
explanation for the low rate of hypoglycaemia is
that some patients may not have received adequate
titration of their insulin dose by their primary care
physicians in accordance with recommended levels,
as indicated by the modest reduction in HbA1c lev-
els observed in the study.
Body weight gain on starting insulin therapy is
usually resulting from amelioration of urinary glycos-
uria and of glucose concentration driven glucose
metabolism (26). That the smallest weight gain was
with detemir, and the greatest with premix insulin, is
consistent with previous reports from randomised
studies (14,25,27). However, the wide variation
(SD ± 5–7 kg) indicates a very diverse experience
among people on any one insulin, considerably
dwarﬁng the 1.5 kg mean difference between the
lowest and the highest insulin groups.
The pattern of persistence with the different treat-
ments did not accord with any of the above variables
associated with diabetes control. Persistence at 1, 2
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Figure 4 Percentage of patients remaining on initial type
of insulin therapy. From initiation, the number of quarters,
patients remain on their initially prescribed insulin, was
calculated (this varied by patient, some remained on their
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protamine Hagedorn
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with glargine and least with NPH. Data on detemir
were limited, but appeared to be similar to that of
NPH in years 1 and 2.
Nevertheless, the detemir data allow some check on
the validity of the results when randomised controlled
trials and observational studies are compared. In the
treating to target in type 2 diabetes (4T) trial (15) det-
emir was also less effective than premix at controlling
HbA1c after 1 year of treatment, but with lower insu-
lin doses and with less weight gain. After 3 years of
treatment, glycaemic control was similar between the
different insulin groups, although detemir required
higher doses than premix but had a lower rate of hypo-
glycaemia (16). Compared with patients initiating
detemir in the PREDICTIVE observational study
(17,18), improvements in glycaemic control in our
study were more modest (1.0% vs. 1.3%) with an
increase in body weight of 1.7 kg compared with a
decrease of 0.5–0.9 kg observed in the PREDICTIVE
cohort. These differences are likely to be attributed to
various factors, including the manner in which sub-
jects are recruited into each study cohort (e.g. enrol-
ment of patients from specialised vs. primary practice
centres) and the degree of insulin titration employed.
However, as a result of the low number of subjects in
our study who were started on detemir, the results
should be interpreted with caution. Interestingly, in
forced titration studies where people are treated to a
glucose target, glucose control tends to be similar
between NPH insulin and insulin glargine, but hypo-
glycaemia rates are very different (by 40%) (28). In
our study, in which hypoglycaemia cannot be reliably
assessed, glucose control was better with insulin glar-
gine compared with NPH as might be expected if
experience of hypoglycaemia limits insulin dose titra-
tion in regular clinical practice.
This observational study has a number of
strengths. It is a population-based assessment of a
large number of people with documented baseline
characteristics over 12 months prior to starting of
insulin. Available data over 12 months and up to
3 years allowed assessment of outcomes over the
medium term and for a period when changes are
likely to be maximal. Importantly, the 3-year data
provides assurance that changes at 12 months were
valid indicators of effects in the longer term, of
importance in a life-long chronic condition. This is
enhanced by the completeness of the follow-up
assessments over that time. Furthermore, the dataset
is reasonably comprehensive for all of the important
variables, including use of oral glucose-lowering
agents as well as insulin dose.
An important aspect here is that the insulin doses
here are derived from real clinical practice, and not
inﬂuenced by any algorithm imposed on the study,
nor even the knowledge of being part of a study (study
effect). Accordingly, the results should be a true reﬂec-
tion of the differences between the different insulins in
clinical practice, and able to be generalised for the pur-
poses of making policy decisions on provision of dia-
betes care, feeding economic models and reviewing the
overall performance of UK care in this area.
The study does have limitations. Perhaps the most
important is that, like all observational studies,
unknown biases may determine which people get
which type of insulin. Both insulin glargine and par-
ticularly insulin detemir were relatively new to the
market at the time of study, and it might be imag-
ined on the one hand that early adopters among
physicians would be keener on better blood glucose
control, but on the other that lesser experience of
the new insulins would limit their optimal use. Since
the data were collected from a large number of pri-
mary practice units with resulting differences in gly-
caemic targets, level of care and physician
experience, this is likely to introduce a level of heter-
ogeneity to the main ﬁndings. We attempted to
account for this by treating the practice as a ran-
dom-effect in the mixed-effects framework.
Another issue is that only 54% of people in the
main study population had measurements at baseline
and at 12 months, despite the use of linearly interpo-
lated data. However, as the baseline characteristics
for this population did not differ compared with the
overall study population, it is likely that the results
are applicable to the main study population.
Some data are not reliably collected in databases like
THIN. Symptomatic hypoglycaemia relies on patient
recall, may not be enquired after, and may not be
recorded unless a self-monitored result is available or
medical-paramedical support is required. The event
rates in this study are below background rates
recorded in randomised controlled trials, and although
the higher rate on premix is consistent with the 4T
study the absolute rates are probably best ignored
(15,16). They are reported only for completeness.
Within the THIN database, we are unable to eval-
uate outcomes in people receiving human vs. ana-
logue premix insulins. At the time of study the likely
mix of human and analogue insulins represented by
our category ‘premix’ would be similar to the UK
market at the time, namely 44⁄56% respectively (29).
Finally, our study cannot determine the reasons
for not achieving better control than mean HbA1c
levels still > 8.0% after 12 months. It is noteworthy
that some sectors of UK primary care remained
unconvinced of the beneﬁts of blood glucose control
despite evidence-based reviews and meta-analyses
(30). A problem here is that it cannot be assumed
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attaining the levels of control found in the current
study would also be found were real clinical practice
to attain better results. Nevertheless, as the results are
consistent with the 1-year ﬁndings of the 4T study
(15), and as the differences in hypoglycaemia rates
tend to be greater at lower HbA1c levels in the rando-
mised studies (31), it is a reasonable assumption that
the differences between the insulins described here
would be no smaller with tighter control.
Despite these shortcomings, observational studies
such as the current report are generally regarded as
an ideal approach to assess the actual health out-
comes of patients in routine care. This is because the
level of care patients receive in clinical trials is often
of a higher standard and not representative of that
provided in daily clinical practice. There are recogni-
sed trade-offs between prospective studies designed
to be internally valid (i.e. randomised controlled tri-
als) and studies aimed at characterising outcomes
observed in actually treated patients (i.e. observa-
tional studies) – each study type adds something to
the evidence base and we have followed accepted
procedures (i.e. inclusion⁄exclusion criteria, statisti-
cal methodology) in minimising the well-known
biases⁄deﬁciencies of database studies.
In summary, in real clinical practice in the UK, in
people with suboptimal glycaemic control with OG-
LDs and lifestyle therapy, insulin is an effective strat-
egy in reducing HbA1c levels. People commenced on
NPH have a modest overall disadvantage in out-
comes when compared with other insulins. Between
group comparisons showed that HbA1c reductions
were greater with insulin glargine, while persistence
with therapy was best on premix at a cost of mod-
estly greater weight gain and higher insulin dosage.
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